ATE378338T1 - Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten - Google Patents
Pyrrolopyridinderivate und deren verwendung als crth2-antagonistenInfo
- Publication number
- ATE378338T1 ATE378338T1 AT05751627T AT05751627T ATE378338T1 AT E378338 T1 ATE378338 T1 AT E378338T1 AT 05751627 T AT05751627 T AT 05751627T AT 05751627 T AT05751627 T AT 05751627T AT E378338 T1 ATE378338 T1 AT E378338T1
- Authority
- AT
- Austria
- Prior art keywords
- crth2 antagonists
- pyrrolopyridine derivatives
- pyrrolopyridine
- derivatives
- crth2
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000005255 pyrrolopyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0413619A GB0413619D0 (en) | 2004-06-17 | 2004-06-17 | Organic compounds |
| GB0507693A GB0507693D0 (en) | 2005-04-15 | 2005-04-15 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378338T1 true ATE378338T1 (de) | 2007-11-15 |
Family
ID=35510318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05751627T ATE378338T1 (de) | 2004-06-17 | 2005-06-16 | Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US7666878B2 (de) |
| EP (1) | EP1761529B3 (de) |
| JP (1) | JP4886680B2 (de) |
| KR (1) | KR101183330B1 (de) |
| AR (1) | AR049443A1 (de) |
| AT (1) | ATE378338T1 (de) |
| AU (1) | AU2005254681B2 (de) |
| BR (1) | BRPI0512060B8 (de) |
| CA (1) | CA2569125C (de) |
| CY (1) | CY1107851T1 (de) |
| DE (1) | DE602005003365T3 (de) |
| DK (1) | DK1761529T3 (de) |
| EC (1) | ECSP067077A (de) |
| ES (1) | ES2294717T7 (de) |
| HR (1) | HRP20080022T4 (de) |
| IL (1) | IL179604A (de) |
| MA (1) | MA28666B1 (de) |
| MX (1) | MXPA06014694A (de) |
| MY (1) | MY144903A (de) |
| NO (1) | NO338319B1 (de) |
| NZ (1) | NZ551439A (de) |
| PE (1) | PE20060301A1 (de) |
| PL (1) | PL1761529T6 (de) |
| PT (1) | PT1761529E (de) |
| RS (1) | RS50552B (de) |
| RU (1) | RU2379309C2 (de) |
| TW (1) | TWI352702B (de) |
| WO (1) | WO2005123731A2 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| GB0525144D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525143D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525337D0 (en) * | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
| NZ570625A (en) | 2006-02-10 | 2011-10-28 | Biomarin Iga Ltd | Treatment of duchenne muscular dystrophy |
| GB0611695D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체 |
| PL2170396T3 (pl) * | 2007-08-03 | 2017-07-31 | Summit (Oxford) Limited | Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| US8101645B2 (en) | 2008-02-15 | 2012-01-24 | Abbott Laboratories | Thienopyrroles and pyrrolothiazoles as new therapeutic agents |
| SMT201700037T1 (it) | 2008-08-15 | 2017-03-08 | Nivalis Therapeutics Inc | Nuovi inibitori pirrolici della s-nitrosoglutatione riduttasi come agenti terapeutici |
| EP2318007B1 (de) | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Neuartige pyrrolhemmer der s-nitrosoglutathion-reduktase als therapeutische mittel |
| WO2010019909A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Pyrrole inhibitors of s-nitrosoglutathione reductase |
| PL2558447T3 (pl) | 2010-03-22 | 2015-03-31 | Idorsia Pharmaceuticals Ltd | Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| EP2457900A1 (de) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten |
| RU2589709C2 (ru) * | 2010-12-23 | 2016-07-10 | Мерк Шарп Энд Домэ Корп. | Хиноксалины и азахиноксалины в качестве модуляторов рецептора crth2 |
| EP2661265B1 (de) | 2010-12-23 | 2017-03-08 | Merck Sharp & Dohme Corp. | Chinoline und aza-chinolines als crth2-rezeptor-modulatoren |
| US9096595B2 (en) | 2011-04-14 | 2015-08-04 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
| BR112014009108A2 (pt) | 2011-10-25 | 2017-04-18 | Shionogi & Co | derivado heterocíclico tendo atividade antagonista de receptor de pgd2 |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| HUE039614T2 (hu) | 2014-03-17 | 2019-01-28 | Idorsia Pharmaceuticals Ltd | Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk |
| KR20160133536A (ko) | 2014-03-18 | 2016-11-22 | 액테리온 파마슈티칼 리미티드 | 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도 |
| WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| WO2016128565A1 (en) | 2015-02-13 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| JP6703090B2 (ja) | 2015-07-23 | 2020-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｒｔｈ２受容体アンタゴニストに対する応答に関連した遺伝的マーカー |
| MX379014B (es) | 2015-09-15 | 2025-03-10 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| CA2999367C (en) | 2015-09-23 | 2023-09-26 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
| WO2017056001A1 (en) * | 2015-09-29 | 2017-04-06 | Novartis Ag | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid |
| WO2017210261A1 (en) * | 2016-05-31 | 2017-12-07 | Concert Pharmaceuticals, Inc. | Deuterated fevipiprant |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| PL3730487T3 (pl) | 2016-06-13 | 2022-08-16 | Gilead Sciences, Inc. | Pochodne azetydyny jako modulatory fxr (nr1h4) |
| CN106188040B (zh) * | 2016-06-28 | 2018-03-23 | 浙江宏鑫染化材料有限公司 | 一种Fevipiprant及其中间体的制备方法 |
| WO2018014867A1 (zh) | 2016-07-21 | 2018-01-25 | 正大天晴药业集团股份有限公司 | 作为crth2抑制剂的三并环类化合物 |
| EP4122464B1 (de) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutische kombinationen zur behandlung von lebererkrankungen |
| KR102378845B1 (ko) | 2017-03-30 | 2022-03-24 | 엑스더블유파마 리미티드 | 이환형 헤테로아릴 유도체 및 이의 제조 및 용도 |
| JOP20190223A1 (ar) * | 2017-04-01 | 2019-09-26 | Novartis Ag | عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك |
| CN116120314A (zh) | 2017-06-30 | 2023-05-16 | 加利福尼亚大学董事会 | 用于调节毛发生长的组合物和方法 |
| WO2019011336A1 (zh) * | 2017-07-14 | 2019-01-17 | 苏州科睿思制药有限公司 | Qaw-039的晶型及其制备方法和用途 |
| WO2019130166A1 (en) * | 2017-12-26 | 2019-07-04 | Mankind Pharma Ltd. | Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid |
| JP7296970B2 (ja) | 2018-01-19 | 2023-06-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | インドール誘導体の結晶形とその調製方法および使用 |
| CN110467612B (zh) * | 2018-05-09 | 2020-09-25 | 新发药业有限公司 | 一种前列腺素d2受体抑制剂化合物的简便制备方法 |
| ES2947089T3 (es) | 2018-09-30 | 2023-08-01 | Xwpharma Ltd | Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| KR20250159079A (ko) | 2019-12-20 | 2025-11-07 | 엑스더블유파마 리미티드 | 4-발레릴옥시부티르산의 합성 방법 |
| JOP20220160A1 (ar) | 2019-12-20 | 2023-01-30 | Nuevolution As | مركبات فعّالة نحو مستقبلات نووية |
| EP4076657A1 (de) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Gegen nukleäre rezeptoren wirksame verbindungen |
| MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| EP4167971A1 (de) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Granulate mit kontrollierter freisetzung von wasserlöslichen pharmazeutischen wirkstoffen |
| EP4167966A1 (de) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Pharmazeutische granulate wasserlöslicher pharmazeutischer wirkstoffe |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| EP4225274A1 (de) | 2020-10-05 | 2023-08-16 | XWPharma Ltd. | Zusammensetzungen aus gamma-hydroxybuttersäurederivaten mit modifizierter freisetzung |
| DK4308086T3 (da) | 2021-03-19 | 2025-11-17 | Xwpharma Ltd | Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320268A (en) | 1964-08-14 | 1967-05-16 | Merck & Co Inc | 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives |
| US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
| GB9319297D0 (en) | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
| US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| ATE182332T1 (de) * | 1994-06-16 | 1999-08-15 | Pfizer | Pyrazolo und pyrrolopyridine |
| TWI262920B (en) | 2000-10-27 | 2006-10-01 | Elbion Ag | New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them |
| US7153852B2 (en) * | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| SE0200356D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| AU2003231509A1 (en) * | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| GB0525143D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525144D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525337D0 (en) * | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
-
2005
- 2005-06-14 MY MYPI20052685A patent/MY144903A/en unknown
- 2005-06-15 PE PE2005000686A patent/PE20060301A1/es active IP Right Grant
- 2005-06-15 AR ARP050102448A patent/AR049443A1/es active IP Right Grant
- 2005-06-16 AU AU2005254681A patent/AU2005254681B2/en not_active Ceased
- 2005-06-16 MX MXPA06014694A patent/MXPA06014694A/es active IP Right Grant
- 2005-06-16 PL PL05751627T patent/PL1761529T6/pl unknown
- 2005-06-16 DK DK05751627T patent/DK1761529T3/da active
- 2005-06-16 RS RSP-2007/0507A patent/RS50552B/sr unknown
- 2005-06-16 JP JP2007515886A patent/JP4886680B2/ja not_active Expired - Fee Related
- 2005-06-16 TW TW094119931A patent/TWI352702B/zh not_active IP Right Cessation
- 2005-06-16 US US11/597,781 patent/US7666878B2/en not_active Expired - Lifetime
- 2005-06-16 WO PCT/EP2005/006493 patent/WO2005123731A2/en not_active Ceased
- 2005-06-16 AT AT05751627T patent/ATE378338T1/de active
- 2005-06-16 EP EP05751627A patent/EP1761529B3/de not_active Expired - Lifetime
- 2005-06-16 DE DE602005003365T patent/DE602005003365T3/de not_active Expired - Lifetime
- 2005-06-16 KR KR1020067026449A patent/KR101183330B1/ko not_active Expired - Fee Related
- 2005-06-16 NZ NZ551439A patent/NZ551439A/en not_active IP Right Cessation
- 2005-06-16 BR BRPI0512060A patent/BRPI0512060B8/pt not_active IP Right Cessation
- 2005-06-16 ES ES05751627T patent/ES2294717T7/es active Active
- 2005-06-16 RU RU2007101277/04A patent/RU2379309C2/ru active
- 2005-06-16 PT PT05751627T patent/PT1761529E/pt unknown
- 2005-06-16 CA CA2569125A patent/CA2569125C/en not_active Expired - Lifetime
- 2005-06-16 HR HR20080022T patent/HRP20080022T4/hr unknown
-
2006
- 2006-11-27 IL IL179604A patent/IL179604A/en active IP Right Grant
- 2006-12-12 EC EC2006007077A patent/ECSP067077A/es unknown
- 2006-12-15 MA MA29535A patent/MA28666B1/fr unknown
-
2007
- 2007-01-17 NO NO20070323A patent/NO338319B1/no not_active IP Right Cessation
-
2008
- 2008-01-10 CY CY20081100039T patent/CY1107851T1/el unknown
-
2010
- 2010-02-03 US US12/699,686 patent/US8470848B2/en active Active
- 2010-02-03 US US12/699,723 patent/US8455645B2/en active Active
-
2013
- 2013-06-05 US US13/910,769 patent/US8791256B2/en not_active Expired - Lifetime
-
2014
- 2014-06-26 US US14/316,503 patent/US9169251B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE378338T1 (de) | Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten | |
| ATE426597T1 (de) | Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel | |
| DE602005023639D1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
| ATE446953T1 (de) | P2x7-rezeptorantagonisten und deren verwendung | |
| ATE459605T1 (de) | Isoxazolinderivate und deren verwendung als herbizide | |
| ATE472546T1 (de) | 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren | |
| DE602005002030D1 (de) | Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors | |
| DE60321043D1 (de) | Biphenylderivate und deren verwendung als fungizide | |
| DE602005004144D1 (de) | Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln | |
| DE602004021037D1 (de) | Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren | |
| ATE409182T1 (de) | Tetrahydrochinolinone und deren verwendung als antagonisten von metabotropen glutamatrezeptoren | |
| DE602006012060D1 (de) | Bicyclische bisamidderivate und deren anwendung als insektizide | |
| ATE478059T1 (de) | Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten | |
| ATE500242T1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten | |
| DE602004022458D1 (de) | Pyrazolderivate und ihre verwendung als orexin-rezeptor-antagonisten | |
| ATE538130T1 (de) | Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten | |
| DE602005011593D1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
| ATE511507T1 (de) | Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten | |
| ATE396185T1 (de) | Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
| ATE427748T1 (de) | Pyridin-derivate und ihre verwendung als urotensin ii antagonisten | |
| ATE482957T1 (de) | Arylessigsäure- und esterderivate und deren verwendung als entzündungshemmende mittel | |
| ATE353083T1 (de) | Naphthyridin-derivate und ihre verwendung als fungizide | |
| ATE517098T1 (de) | Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren | |
| DE602005022060D1 (de) | Diaminoalkohole und deren verwendung als renininhibitoren | |
| FI20060188L (fi) | Modifioidut IL-4-muteiinin reseptorin antagonistit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1761529 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 1761529 Country of ref document: EP |